Arcadia Biosciences, Inc. (RKDA): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de la biotechnologie agricole, Arcadia Biosciences, Inc. (RKDA) émerge comme une force pionnière, transformant la façon dont nous abordons le développement des cultures et l'agriculture durable. Grâce à un génie génétique innovant et à des recherches scientifiques avancées, cette entreprise dynamique redéfinit les possibilités agricoles en créant des variétés de cultures qui peuvent résister à des défis environnementaux extrêmes. En développant des semences résistantes à la sécheresse et tolérantes au sel, Arcadia n'améliore pas seulement la productivité agricole, mais remodeler fondamentalement notre compréhension de la façon dont la technologie peut relever les défis mondiaux de la sécurité alimentaire.

Arcadia Biosciences, Inc. (RKDA) - Modèle commercial: partenariats clés

Institutions et universités de recherche agricole

Arcadia Biosciences a établi des partenariats avec les institutions de recherche suivantes:

Institution	Focus de la collaboration
Université de Californie, Davis	Recherche d'amélioration génétique des cultures
Donald Danforth Plant Science Center	Développement avancé de la biotechnologie agricole

Sociétés de semences et partenaires de développement des cultures

Les partenariats clés des entreprises de semences comprennent:

• S&W Seed Company
• Mahyco Seeds (Inde)

Agences agricoles du gouvernement

Agence	Type de collaboration	Année établie
Service de recherche agricole de l'USDA	Financement de la recherche et transfert de technologie	2015
California Department of Food and Agriculture	Support de l'innovation des cultures	2016

Collaborateurs de biotechnologie et de science des cultures

Partenariats stratégiques de biotechnologie:

• Science des cultures de Bayer
• Corteva Agriscience

Investisseurs technologiques agricoles

Investisseur	Montant d'investissement	Année
Cultivien Sandbox Ventures	5,2 millions de dollars	2018
Khosla Ventures	7,3 millions de dollars	2019

Investissements totaux de partenariat: 12,5 millions de dollars

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: activités clés

Développement des traits agricoles et génie génétique

En 2024, Arcadia Biosciences se concentre sur la modification génétique des cultures avec des traits spécifiques:

Type de culture	Focus de modification génétique	Étape de développement
Blé	Efficacité d'utilisation de l'azote	Recherche avancée
Riz	Efficacité d'utilisation de l'eau	Développement commercial
Soja	Tolérance au stress	Essais initiaux

Recherche et innovation de la résilience des cultures

Investissement en recherche dans les technologies de résilience des cultures:

• Dépenses annuelles de R&D: 3,2 millions de dollars
• Personnel de recherche: 42 scientifiques
• Projets de recherche actifs: 7 principaux programmes de modification des cultures

Développement de technologies agricoles durables

Zone technologique	Investissement	Statut de brevet
Efficacité d'utilisation de l'azote	1,5 million de dollars	4 brevets en attente
Traits de conservation de l'eau	1,2 million de dollars	3 brevets accordés

Gestion et licence de propriété intellectuelle

Détails du portefeuille de propriété intellectuelle:

• Brevets actifs totaux: 23
• Revenus de licences de brevet: 750 000 $ par an
• Couverture des brevets géographiques: États-Unis, Canada, Brésil

Commercialisation des produits et développement du marché

Catégorie de produits	Pénétration du marché	Génération de revenus
Graines d'efficacité d'utilisation de l'azote	12% de part de marché agricole	4,3 millions de dollars
Traits de culture économe en eau	8% de part de marché agricole	3,1 millions de dollars

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: Ressources clés

Installations de recherche avancée en biotechnologie

En 2024, Arcadia Biosciences maintient des installations de recherche situées à Davis, en Californie. Le total des biens de recherche et développement de la société, de l'usine et de l'équipement était évalué à 2,3 millions de dollars au 31 décembre 2022.

Emplacement de l'installation	Focus de recherche	En pieds carrés
Davis, Californie	Biotechnologie agricole	Environ 25 000 pieds carrés

Technologies de modification génétique propriétaire

Arcadia Biosciences détient plusieurs familles de brevets couvrant les technologies de modification génétique.

• Portfolio total des brevets: 37 brevets délivrés
• Couverture des brevets: États-Unis, Europe, Chine et autres marchés agricoles clés
• Zones technologiques: efficacité d'utilisation de l'azote, optimisation de l'eau, tolérance au stress des cultures

Personnel scientifique et de recherche qualifié

Depuis le rapport annuel de 2022, Arcadia Biosciences a utilisé 24 membres du personnel de recherche et développement à temps plein.

Catégorie des employés	Nombre d'employés	Le plus élevé
Chercheurs de doctorat	12	Doctorat en sciences végétales
Chercheurs de niveau Masters	8	MS en biotechnologie
Chercheurs de niveau baccalauréat	4	BS en sciences agricoles

Portefeuille de brevets de traits agricoles

Arcadia Biosciences a développé des traits agricoles clés avec un potentiel commercial.

• Trait d'efficacité d'utilisation de l'azote (NUE)
• Trait d'optimisation de l'eau
• Trait de tolérance au sel

Bibliothèques germperas de semences

La société maintient des bibliothèques génétiques pour plusieurs espèces de cultures.

Type de culture	Variantes du matériel génétique	Statut de modification génétique
Riz	127 variantes uniques	Partiellement modifié
Blé	84 variantes uniques	En cours de développement
Canola	56 variantes uniques	Sous licence commerciale

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: propositions de valeur

Rendement des cultures et tolérance au stress accrus

Arcadia Biosciences se concentre sur le développement de variétés de cultures avec des traits génétiques améliorés pour améliorer les performances agricoles.

Type de culture	Amélioration des rendements	Tolérance au stress
Riz	Augmentation du rendement de 15 à 20%	Résistance élevée au sel et à la sécheresse
Blé	10 à 15% d'amélioration des rendements	Efficacité améliorée d'utilisation de l'eau

Amélioration de la durabilité agricole

L'entreprise développe des technologies génétiques pour soutenir les pratiques agricoles durables.

• Amélioration de l'efficacité d'utilisation de l'azote: réduction jusqu'à 30% des besoins en engrais
• Technologies de conservation de l'eau pour le développement des cultures
• Réduction des stratégies d'entrée chimique

Impact environnemental réduit de l'agriculture

Innovations génétiques ciblant la conservation de l'environnement dans l'agriculture.

Métrique environnementale	Pourcentage d'amélioration
Réduction des gaz à effet de serre	25% de réduction potentielle
Efficacité d'utilisation de l'eau	Diminution potentielle de 40%

Variétés de cultures tolérantes à la sécheresse et au sel

Génie génétique spécialisé pour les environnements agricoles difficiles.

• Variétés de riz tolérantes à la sécheresse développées pour les marchés asiatiques
• Soules de blé résistantes au sel pour les terres agricoles marginales
• Modifications génétiques permettant la survie des cultures dans des conditions de 20 à 30% plus difficiles

Accrue de productivité agricole et d'efficacité

Technologies conçues pour maximiser les performances des cultures et la rentabilité des agriculteurs.

Métrique de productivité	Amélioration potentielle
Augmentation du rendement des cultures	15-25% sur plusieurs types de cultures
Réduction des coûts de production	10-20% grâce à l'efficacité génétique

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: relations avec les clients

Support technique direct pour les clients agricoles

En 2024, Arcadia Biosciences fournit un support technique direct à travers:

Canal de support	Méthode de contact	Temps de réponse
Ligne d'assistance agricole	E-mail / téléphone	48-72 heures
Portail technique en ligne	Support Web	Accès 24 heures

Partenariats de recherche collaborative

Métriques de collaboration de recherche actuelles:

• 7 partenariats de recherche universitaire actifs
• 3 institutions de recherche agricole internationales
• Investissement annuel de collaboration de recherche: 2,1 millions de dollars

Développement de traits de cultures personnalisés

Type de culture	Services de développement de traits	Temps de développement moyen
Riz	Efficacité d'utilisation de l'azote	36 mois
Blé	Résistance à la sécheresse	42 mois

Services de conseil scientifique

Répartition des services de conseil:

• Taux de consultation des traits génétiques: 250 $ - 500 $ l'heure
• 6 consultants scientifiques dédiés
• Revenus de consultation annuels: 1,4 million de dollars

Partage des connaissances technologiques agricoles

Plateforme de partage des connaissances	Base d'utilisateurs	Engagement annuel
Webinaires en ligne	1 200 professionnels agricoles	18 séances
Libères blancs techniques	3 500 abonnés	12 publications

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les entreprises agricoles

En 2024, Arcadia Biosciences maintient une équipe de vente directe spécialisée axée sur les marchés de la biotechnologie agricole. L'équipe commerciale cible environ 127 sociétés agricoles à travers l'Amérique du Nord.

Type de canal de vente	Nombre d'entreprises cibles	Couverture géographique
Ventes agricoles directes	127	Amérique du Nord

Salons et conférences agricoles

Arcadia Biosciences participe à des événements clés de la biotechnologie agricole pour présenter ses technologies.

• Participation annuelle à 6 à 8 conférences agricoles majeures
• Associé à la conférence estimée: 3 200 professionnels de l'industrie par an
• Les conférences clés incluent les événements mondiaux de la Fédération des semences AG World

Publications et présentations scientifiques en ligne

L'entreprise tire parti des plateformes de communication scientifique numériques pour la diffusion technologique.

Type de publication	Publications annuelles	Portée numérique
Revues scientifiques	12-15	Environ 45 000 chercheurs

Réseaux de distribution des entreprises de semences

Arcadia Biosciences collabore avec des partenaires stratégiques de distribution de semences.

• Partenariats actifs avec 17 réseaux de distribution de semences
• Couverture de distribution dans 9 régions agricoles
• Port de marché potentiel total: 42 millions d'acres

Plate-forme de marketing numérique et de communication scientifique

Les canaux numériques sont essentiels pour la communication technologique et l'engagement du marché.

Plate-forme numérique	Adeptes / abonnés	Taux d'engagement
Liendin	4,732	3.7%
Plateformes de recherche scientifique	2,890	4.2%

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: segments de clientèle

Producteurs agricoles commerciaux

En 2024, Arcadia Biosciences cible les producteurs agricoles commerciaux avec des solutions de biotechnologie agricole spécifiques.

Caractéristique du segment	Données spécifiques
Taille totale du marché adressable	Marché de la biotechnologie agricole de 58,7 milliards de dollars
Clientèle potentielle	Environ 2,2 millions de fermes commerciales en Amérique du Nord
Investissement annuel moyen par ferme	375 000 $ en solutions de biotechnologie

Sociétés d'élevage de semences

Arcadia Biosciences fournit des technologies génétiques spécialisées pour les entreprises de sélection de graines.

• Valeur marchande mondiale des semences: 64,3 milliards de dollars
• Nombre de clients potentiels de l'entreprise d'élevage de semences: 187 dans le monde
• Valeur de licence de technologie moyenne: 1,2 million de dollars par trait génétique

Agences agricoles du gouvernement

Les agences gouvernementales de recherche et développement agricole représentent un segment de clientèle essentiel.

Type d'agence	Investissement potentiel
Financement de la recherche USDA	Budget annuel de 3,1 milliards de dollars
Centres de recherche agricole internationaux	Investissement de recherche collective de 1,7 milliard de dollars

Organisations internationales de recherche agricole

Arcadia Biosciences collabore avec des organisations internationales de recherche agricole.

• Nombre de partenaires de recherche internationaux potentiels: 72
• Projet de recherche collaborative Valeur moyenne: 850 000 $
• Couverture géographique: 46 pays

Entreprises agricoles à grande échelle

Les grandes entreprises agricoles représentent un segment de clientèle important pour Arcadia Biosciences.

Caractéristique de l'entreprise	Données spécifiques
Total de grandes opérations agricoles	12 400 fermes de plus de 1 000 acres
Investissement technologique annuel moyen	1,5 million de dollars par entreprise
Pénétration potentielle du marché	17,6% des entreprises agricoles à grande échelle

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Arcadia Biosciences a déclaré des frais totaux de recherche et de développement de 4,7 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage des dépenses totales
2023	4,7 millions de dollars	38.5%
2022	5,2 millions de dollars	42.3%

Protection et entretien de la propriété intellectuelle

Les coûts annuels de protection de la propriété intellectuelle pour Arcadia Biosciences étaient d'environ 350 000 $ en 2023.

• Frais de dépôt de brevets: 175 000 $
• Coûts de consultation juridique: 125 000 $
• Enregistrement des marques: 50 000 $

Salaires du personnel scientifique

La rémunération totale du personnel scientifique pour 2023 était de 3,6 millions de dollars.

Catégorie de personnel	Salaire annuel moyen	Nombre d'employés
Scientifiques supérieurs	$185,000	8
Associés de recherche	$85,000	15
Techniciens de laboratoire	$65,000	12

Investissements infrastructures technologiques

Les investissements sur les infrastructures technologiques pour 2023 ont totalisé 1,2 million de dollars.

• Équipement de laboratoire: 650 000 $
• Ressources logicielles et informatiques: 350 000 $
• Maintenance des infrastructures informatiques: 200 000 $

Coûts de marketing et de développement commercial

Les dépenses de marketing et de développement commercial pour 2023 étaient de 1,5 million de dollars.

Activité marketing	Dépense
Participation de la conférence et du salon	$450,000
Marketing numérique	$350,000
Voyage du développement des entreprises	$250,000
Matériel promotionnel	$150,000
Compensation de l'équipe de vente	$300,000

Arcadia Biosciences, Inc. (RKDA) - Modèle d'entreprise: Strots de revenus

Frais de licence de traits

En 2024, Arcadia Biosciences génère des revenus grâce à des frais de licence de traits pour les innovations de biotechnologie agricole. Les accords de licence de l'entreprise se concentrent sur des traits génétiques spécifiques qui améliorent les performances des cultures.

Type de trait	Gamme de frais de licence	Revenus annuels estimés
Efficacité d'utilisation de l'azote	50 000 $ - 250 000 $ par licence	$375,000
Tolérance à la sécheresse	75 000 $ - 300 000 $ par licence	$525,000

Redevances de la technologie des semences

Les flux de redevances sont générés à partir de technologies de semences commercialisées développées par Arcadia Biosciences.

• Taux de redevance des semences: 3 à 5% des ventes de semences brutes
• Revenus de redevances annuelles estimées: 1,2 million de dollars
• Zones technologiques clés: blé, riz, canola

Accords de collaboration de recherche

Arcadia Biosciences établit des accords de collaboration de recherche avec des sociétés agricoles et biotechnologiques.

Partenaire de collaboration	Valeur du contrat	Durée
Cabinet de recherche agricole	$450,000	18 mois
Biotechnology Corporation	$675,000	24 mois

Contrats de développement de produits

La société génère des revenus grâce à des contrats de développement de produits spécialisés en biotechnologie agricole.

• Valeur du contrat moyen: 250 000 $ - 500 000 $
• Revenu total du contrat annuel: 2,1 millions de dollars
• Types de contrats: développement de traits génétiques, amélioration des cultures

Ventes et transferts de propriété intellectuelle

Arcadia Biosciences monétise sa propriété intellectuelle par le biais de transferts stratégiques de vente et de technologie.

Catégorie IP	Valeur de vente	Fréquence
Brevets de traits génétiques	$350,000 - $750,000	2-3 par an
Transfert de technologie	$250,000 - $500,000	1-2 par an

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Value Propositions

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a clear value proposition centered on high-growth consumer wellness brands supported by a foundation of operational discipline. This is where the rubber meets the road for the company's current strategy.

High-growth, better-for-you consumer product in Zola coconut water

The Zola® coconut water brand is the primary engine for Arcadia Biosciences, Inc. (RKDA) right now. For the first nine months of 2025, the company's total revenue of $3.96 million consisted entirely of Zola coconut water sales. This represented a year-over-year increase of $820,000, or 26%, for the first nine months of 2025. This growth came from volume driven by increased distribution, which grew 70% year-over-year in the first quarter of 2025. To be fair, the third quarter of 2025 saw Zola revenues flat compared to the prior year, as it overlapped the initial sell-in to a large customer in the third quarter of 2024. Still, the year-to-date performance shows a strong consumer pull.

Consistent operational efficiency with gross margins exceeding 30%

Arcadia Biosciences, Inc. (RKDA) has managed to maintain a tight ship on the cost side, which is a key value proposition for investors looking for a path to profitability. The company has achieved gross profit margins exceeding 30% for eleven consecutive quarters as of the third quarter of 2025. Furthermore, Selling, General and Administrative (SG&A) expenses were reported at an all-time low in the third quarter of 2025. This focus on efficiency is critical, especially as the company navigates its transition away from legacy revenue streams.

Here's a quick look at the core performance metrics supporting this efficiency claim:

Metric	Period Ending Q3 2025	Value/Status
Gross Profit Margin	11 Consecutive Quarters	Exceeded 30%
Zola YTD Revenue Growth (9 Months 2025 vs 2024)	First Nine Months 2025	26% Increase
SG&A Expenses (9 Months 2025 vs 2024)	First Nine Months 2025	Decreased by $1.6 million

Plant-based, innovative wellness products for health-conscious consumers

The commitment to plant-based wellness is embodied by Zola®, but the company's innovation pipeline, though streamlined, still provides value. Arcadia Biosciences, Inc. (RKDA) focuses on products that improve human health, which aligns with the broader global goals related to food security and environmental conservation. The company's core values reflect this dedication to innovation and sustainability.

• Focus on plant-based, innovative wellness.
• Zola® sales growth driven by volume, not price increases in 2024 or 2025.
• Net income attributable to common stockholders for Q1 2025 was $2.6 million.

Non-GMO, proprietary wheat grain technology (licensed to Above Food)

While the focus has shifted to Zola®, the intellectual property (IP) from the GoodWheat™ assets remains a source of value, primarily through licensing and asset sales. Arcadia Biosciences, Inc. (RKDA) continues to hold equity in Above Food Corp. following the sale of the GoodWheat™ brand. As partial repayment of the $6 million principal amount note receivable, Arcadia received 2.7 million shares of Above Food Ingredients Inc. stock. Furthermore, the company recognized a $2.8 million gain in the first nine months of 2025 related to the agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents. You should note, however, that the company recognized a significant $4.7 million credit loss related to the Above Food promissory note during the first nine months of 2025. Finance: draft 13-week cash view by Friday.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Relationships

You're looking at how Arcadia Biosciences, Inc. (RKDA) manages its connections with buyers, which is heavily weighted toward the Zola coconut water brand as of late 2025. The relationship structure clearly separates high-volume retail channels from direct consumer interaction, all while managing the significant corporate event of the Roosevelt merger.

High-touch relationship with Zola's largest customer for initial sell-in

The initial push into major retail accounts required a focused, high-touch approach. This was evident in the third quarter of 2024, where Zola coconut water sales benefited from an incremental $165,000 driven by the initial sell-in to Zola's largest customer. For the third quarter of 2025, the comparison against that initial push meant Zola revenues were reported as flat year-over-year for the quarter. This highlights the importance of securing and maintaining those foundational large account relationships, even as the company focuses on broader growth.

Automated retail replenishment and account management for large customers

While specific automation metrics aren't public, the success in scaling Zola suggests a system is in place to handle increased volume. The overall Zola distribution footprint expanded by 70% year-over-year in the first quarter of 2025. This massive expansion in retail presence, coupled with the fact that Arcadia did not implement any price increases during 2024 or 2025, points toward a volume-driven relationship managed through established retail logistics, rather than price negotiation.

Direct-to-consumer engagement via digital and social media channels

Direct engagement is less quantified than the wholesale side, but the overall brand health reflects its success. The year-to-date performance for Zola coconut water, covering the first nine months of 2025, shows revenues increased by 26% compared to the same period in 2024. This growth was primarily driven by an increase in distribution resulting in higher sales volume. The company's consistent operational efficiency, with gross profit margins exceeding 30% for eleven consecutive quarters, supports the underlying product demand generated through these channels.

Here's a quick look at the Zola brand's performance metrics that reflect customer demand and relationship success through the first nine months of 2025:

Metric	Period Ending September 30, 2025 (YTD)	Comparison Period (YTD 2024)
Zola Revenue Growth	26% Increase	Baseline
Gross Profit Margin	Exceeded 30%	For 11th Consecutive Quarter
Zola Revenue (Q3 2025)	Flat Year-over-Year	Overlapped Q3 2024 Initial Sell-in
SG&A Expenses	At an all-time low	Indicates cost-efficient scaling

Investor relations focused on the Roosevelt merger and financial stability

Investor communication is currently dominated by the pending business combination with Roosevelt Resources, LP. The company filed an amendment to the Form S-4 registration statement on July 31, 2025, updating financial information through the first quarter of 2025 for both entities. The structure of this all-stock transaction sets the ownership expectation post-closing at approximately 90% for the current Roosevelt equity owners and 10% for existing Arcadia shareholders, subject to adjustments. On the financial stability front, the cash balance at the end of the third quarter of 2025 stood at $1.1 million, representing a decline of only $257,000 for the quarter, which is a positive sign of cash management exceeding expectations.

Key focus areas for investor confidence include:

• Gross profit margins exceeding 30% for 11 straight quarters.
• Selling, General, and Administrative (SG&A) expenses at an all-time low.
• Net income attributable to common stockholders of $856,000 in Q3 2025.
• Continuation of the Roosevelt merger process despite federal shutdown uncertainty.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Channels

You're looking at how Arcadia Biosciences, Inc. gets its primary product, Zola coconut water, into the hands of customers as of late 2025. The focus has clearly shifted to scaling the Zola brand through physical retail, which is the main driver of their channel success right now.

Traditional grocery and retail chains for Zola product placement

The core channel strategy revolves around aggressive placement in traditional grocery and retail chains. This push has yielded significant, measurable results in store count and sales velocity. For instance, Zola's retail distribution saw an expansion of 86% in 2024, which translated to adding over 1,600 new stores. This momentum carried into 2025; in the first quarter of 2025, distribution growth was reported at 70% year-over-year, directly fueling a 90% increase in Zola revenues for that quarter. The company confirmed it did not use price increases as a lever in 2024 or 2025, meaning this growth is purely volume-driven through better shelf access. The strategy is about maximizing physical footprint.

E-commerce platforms for direct-to-consumer sales

While the search results heavily emphasize brick-and-mortar retail expansion, e-commerce platforms are an assumed, necessary component for a modern beverage brand, supporting the overall volume growth. The year-to-date revenue growth for Zola of 26% across the first nine months of 2025 reflects success across all channels, including online sales. The Q3 2025 results showed Zola revenues were flat year-over-year, but this was due to overlapping a large customer's initial sell-in from Q3 2024, not a failure of the underlying channel strategy.

Third-party distributors and brokers for national retail reach

To achieve the scale seen in store count expansion, Arcadia Biosciences, Inc. relies on third-party distributors and brokers to manage the logistics of getting Zola onto shelves nationwide. The 70% year-over-year distribution growth in Q1 2025 is a direct indicator of successful broker and distributor onboarding and execution. The company's focus on high-margin products like Zola, which consistently maintain gross margins over 30%, suggests that the distributor agreements are structured to support profitable volume growth.

Here's a quick look at how the key product channel metrics stacked up:

Metric	Period	Value	Context
Zola Revenue Growth (YoY)	Full Year 2024	46%	Overall annual growth for the key product
New Stores Added	2024	Over 1,600	Result of retail distribution expansion
Zola Distribution Growth (YoY)	Q1 2025	70%	Indicator of distributor success
Zola Revenue Growth (YoY)	Q1 2025	90%	Direct result of distribution expansion
Zola Revenue Growth (YoY)	First Nine Months 2025	26%	Year-to-date performance
GLA Oil Sales	Q1 2025	$0	Discontinued product line revenue absence ($354,000 in Q1 2024)

SEC filings and investor calls for capital market communication

Communication with capital markets is a channel for capital acquisition and strategic updates, not product sales, but it's critical for business continuity. Arcadia Biosciences, Inc. actively uses SEC filings to formalize these communications. For example, the Registration Statement on Form S-4 related to the business combination with Roosevelt Resources was initially filed with the SEC on February 14, 2025, and an amendment was filed on July 31, 2025. Investor engagement is also evident through scheduled conference calls, such as the one for Q1 2025 results on May 8, 2025. The company ended 2024 with $4.2 million in cash, and by Q3 2025, the cash balance was $1.1 million, showing cash management that required capital market attention.

Key communication milestones included:

• Filing of Form S-4 Registration Statement: February 14, 2025.
• Q1 2025 Results Conference Call: May 8, 2025.
• Sale of select patents for $750,000 announced in Q1 2025.
• Filing of pre-effective amendment to Form S-4: July 31, 2025.
• Q3 2025 Financial Results reported on November 7, 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Segments

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a company in a sharp pivot, moving away from its agricultural biotech roots toward a consumer wellness focus. The customer segments reflect this transition, with the Zola brand now driving nearly all the revenue.

Health and wellness-focused consumers seeking plant-based beverages

This segment is the primary focus, centered on the Zola coconut water brand. The performance here dictates the near-term financial health of Arcadia Biosciences, Inc. (RKDA).

• Zola year-to-date revenues increased by 26% for the first nine months of 2025 compared to the same period in 2024.
• The dollar increase in Zola revenue year-to-date (first nine months of 2025) was $820,000.
• Zola Q1 2025 revenue showed a 90% year-over-year increase.
• Zola Q2 2025 revenue grew 24% year-over-year.
• Zola Q3 2025 revenues were flat year-over-year.
• The company has maintained gross profit margins exceeding 30% for eleven consecutive quarters as of Q3 2025.
• No price increases were implemented by Arcadia Biosciences, Inc. (RKDA) during 2024 or 2025.
• Total revenue for the first nine months of 2025 was $3.96 million, consisting entirely of Zola coconut water sales.
• Total revenue for Q3 2025 was $1.302 million.

Large national and regional grocery retailers and distributors

These partners are the essential conduit to the health and wellness consumers. Their stocking decisions directly impact Zola's sales volume.

• Zola's year-to-date growth in 2025 was primarily driven by an increase in distribution.
• As of Q1 2025, Zola distribution had grown 70% year-over-year.
• Retail distribution for Zola nearly doubled in 2024.
• The Q3 2024 sales included an incremental $165,000 from the initial sell-in to a large customer, which created a tough comparison for Q3 2025.

Institutional and individual investors focused on turnaround plays

This segment views Arcadia Biosciences, Inc. (RKDA) through the lens of its corporate restructuring and the pending business combination, which is a major factor in investor sentiment.

Financial/Event Metric	Value as of Late 2025 Data
Cash Balance (as of September 30, 2025)	$1.1 million
Credit Loss Recognized on Note Receivable (as of September 30, 2025)	$4.7 million
Q3 2025 Net Income Attributable to Common Stockholders	$856,000
Q3 2025 Earnings Per Share (EPS)	$0.63 per share
Q3 2024 Net Loss Attributable to Common Stockholders	$1.6 million
Q3 2024 Loss Per Share (EPS)	$1.18 per share
Expected Post-Closing Equity Split (Roosevelt Partners / Arcadia Shareholders)	90% / 10%
Analyst Consensus Rating (Last 12 Months)	Sell (1 of 1 analyst rating)
Analyst Revenue Forecast (Average for 2025)	$6.1M
Trailing Twelve Months (TTM) Revenue (as of late 2025)	$5.17 Million USD

The pending business combination with Roosevelt Resources is still in progress, with an amended exchange agreement filed in July 2025.

Strategic partners interested in agricultural biotechnology IP

This segment relates to the monetization and wind-down of legacy agricultural assets, which provided non-recurring revenue and gains in prior periods.

• GLA oil sales, which were present in 2024, were absent in the first nine months of 2025.
• GLA oil sales in the first nine months of 2024 totaled $701,000.
• GLA oil sales in Q3 2024 totaled $217,000.
• Arcadia Biosciences, Inc. (RKDA) sold select patents for $750,000 in March 2025.
• A $2.8 million gain was recognized in 2025 from an agreement with Bioceres Crop Solutions Corp regarding reduced gluten and oxidative stability patents.
• A $4.0 million gain occurred in 2024 from the sale of RS durum wheat patents to Corteva.
• The company eliminated $1 million in contingent liabilities year-to-date Q2 2025 via an agreement with Bioseed Research India.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Cost Structure

Cost of revenues, primarily for Zola product manufacturing and logistics

For the first nine months of 2025, Cost of revenues increased by $253,000, representing a 12% rise compared to the same period in 2024, mainly due to Zola coconut water costs.

Specifically for Zola, the cost of revenues for the first nine months of 2025 grew by $472,000, which is a 25% increase, directly linked to the 26% growth in Zola sales year-to-date.

Looking at the quarterly progression:

• Cost of revenues for the first quarter of 2025 rose by $211,000, or 45%, entirely from Zola product costs.
• Zola cost of revenues in the first quarter of 2025 increased by $244,000, or 56%.
• In the second quarter of 2025, Cost of revenues increased $191,000, or 30%, consisting only of Zola coconut water costs.
• Zola cost of revenues grew $204,000, or 33%, in the second quarter of 2025.

For context, the total cost of revenues for the full year 2024 was $3 million.

Selling, General, and Administrative (SG&A) expenses, reduced by $1.6 million year-to-date Q3 2025

Arcadia Biosciences, Inc. achieved a significant reduction in overhead. SG&A expenses decreased by $1.6 million for the first nine months of 2025 when compared to the same nine-month period in 2024.

This reduction was $671,000 just in the third quarter of 2025.

The decrease in SG&A for the first quarter of 2025 alone was $324,000, or 16%.

The full-year 2024 SG&A expenses totaled $9.6 million.

Transaction-related costs for the Roosevelt Resources business combination

Costs associated with the strategic transactions appeared in prior periods, influencing the current period's expense comparison. For instance, SG&A expenses for the fourth quarter of 2024 included $700,000 in transaction-related costs.

Total transaction-related costs recorded in the full year 2024, covering the GoodWheat asset sale and the pending Roosevelt Resources transaction, amounted to $2.0 million.

More recently, the CEO noted almost $700,000 in transaction fees during the second quarter of 2025.

Significant non-cash credit loss of $4.7 million on the Above Food note receivable

A major non-cash impact on the cost structure for the first nine months of 2025 was the $4.7 million credit loss recognized related to the note receivable from Above Food.

This loss was heavily weighted in the second quarter of 2025, where a $4.5 million credit loss was established as a reserve for the outstanding principal, accrued interest, and related receivables after the stock election fulfillment.

Employee-related costs for a streamlined corporate team

The year-over-year improvement in SG&A for the first nine months of 2025 was primarily attributed to the absence of certain 2024 expenses.

The reduction was driven by:

• Operating costs present in 2024 but absent in 2025.
• Employee related costs in 2024 that were not incurred in 2025, reflecting the streamlined corporate team.

Here is a snapshot of key financial movements impacting the cost structure for the first nine months of 2025 compared to the first nine months of 2024 (amounts in thousands, unless noted):

Cost Component	Change (9M 2025 vs 9M 2024)	Detail/Context
Cost of Revenues	Increase of $253	Primarily Zola product costs.
Zola Cost of Revenues	Increase of $472 (or 25%)	Driven by 26% increase in Zola sales.
SG&A Expenses	Decrease of $1,600	Reflects streamlined operations and absence of 2024 costs.
Credit Loss (Above Food)	$4,700 recognized	Non-cash credit loss on note receivable for 9M 2025.
Transaction Fees (Q2 2025)	Almost $700	Fees incurred during the second quarter of 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Revenue Streams

You're looking at how Arcadia Biosciences, Inc. is bringing in money as of late 2025, which is heavily focused on the Zola® brand now that legacy businesses are largely exited. The revenue picture is a mix of product sales and one-time asset monetization events.

The Trailing Twelve Months (TTM) total revenue for Arcadia Biosciences, Inc. stands at approximately $5.17 million USD as of the latest reports. For the third quarter of 2025 alone, revenue was reported at $1.3 million.

The primary driver for product revenue is Zola® coconut water. For the first nine months of 2025, Zola® year-to-date revenues showed strong growth, increasing by 26% year-over-year. This growth helped offset the absence of sales from discontinued product lines, such as GLA oil, which generated $701,000 in the first nine months of 2024.

Monetization of intellectual property (IP) provided significant, non-recurring income. In the first quarter of 2025, Arcadia Biosciences, Inc. completed a sale of select patents for $750,000. Furthermore, for the first nine months of 2025, the company recognized a gain of $2.8 million related to an agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents.

Non-operating income from investments also contributed materially to the bottom line. Specifically, in the third quarter of 2025, Arcadia Biosciences, Inc. recognized an unrealized gain of $1.7 million on its holding of Above Food Ingredients Inc. common stock. This stock was received as partial repayment of the note receivable from the prior sale of the GoodWheatTM assets.

The company still retains potential for future revenue from its legacy IP, though specific amounts are not currently realized or guaranteed. This is the area where past licensing and trait sales occurred, such as the $4 million one-time payment from Corteva Agriscience for the Resistant Starch Durum trait in 2024.

Here's a quick look at the key components contributing to the revenue picture:

Revenue Stream Component	Latest Reported Figure/Metric	Period/Context
TTM Total Revenue	$5.17 Million USD	Trailing Twelve Months
Zola® Coconut Water YTD Revenue Growth	26% increase	Year-to-Date Q3 2025
Q1 2025 Patent Sale Proceeds	$750,000	Q1 2025
Q3 2025 Unrealized Gain on Stock	$1.7 million	Q3 2025
2025 IP Transfer Gain (Partial)	$2.8 million gain	First Nine Months of 2025

The current revenue focus is clearly on scaling the Zola® brand, which is the sole product line now generating sales revenue. The IP monetization and stock gains are important for cash flow but are not sustainable, recurring revenue streams in the same way product sales are.

You should track the Q4 2025 results closely to see if the Zola® growth rate holds up against the prior year's large customer sell-in benefit.

• Zola® is the primary product revenue source.
• Legacy IP monetization provided one-time cash events.
• Unrealized gains on equity holdings impact reported income.
• No price increases were implemented during 2024 or 2025.

Finance: draft 13-week cash view by Friday.